1
|
Sapkota R, Munt DJ, Kincaid AE, Dash AK. Liposomes and transferosomes in the delivery of papain for the treatment of keloids and hypertrophic scars. PLoS One 2023; 18:e0290224. [PMID: 38100466 PMCID: PMC10723692 DOI: 10.1371/journal.pone.0290224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2023] [Accepted: 08/04/2023] [Indexed: 12/17/2023] Open
Abstract
Hypertrophic scars and keloids are characterized by an excessive collagen deposition. The available treatment options are invasive and can result in recurrence of scar formation. Using liposomes and transferosomes for the topical delivery of papain, a proteolytic enzyme, can be effective treatment. The objective of the study is to formulate papain-loaded liposomes and transferosomes, characterize the formulations, and study in vitro permeation using shed snake skin and Sprague-Dawley rat skin as models for stratum corneum and full thickness skin. Papain-loaded liposomes and transferosomes were formulated using the thin-film hydration method for the delivery of papain across the stratum corneum barrier. An in vitro permeation study carried out using shed-snake skin and Sprague-Dawley rat skin models showed that transferosomes were able to deliver papain across the stratum corneum barrier, while papain solution and papain liposomes were not able to cross the barrier. However, transferosomes were not able to deliver papain across the full thickness rat skin model suggesting the deposition of papain loaded transferosomes in the epidermal or dermal layer of skin. In addition, an ex-vivo model was used to analyze the effect of papain exposure on the morphology of the epidermis taken from rat skin exposed to papain solution, papain in transferosomes and papain in liposomes. Papain in solution resulted in a noticeable degradation of the epidermis, but when embedded in either transferosomes or liposomes there was no noticeable change when compared to control animals. The cytotoxicity study performed using HeLa cells showed that the cells were viable at papain concentrations lower than 0.01 mg/ml.
Collapse
Affiliation(s)
- Rachana Sapkota
- Department of Pharmacy Sciences, School of Pharmacy and Health Profession, Creighton University, Omaha, Nebraska, United States of America
| | - Daniel J. Munt
- Department of Pharmacy Sciences, School of Pharmacy and Health Profession, Creighton University, Omaha, Nebraska, United States of America
| | - Anthony E. Kincaid
- Department of Pharmacy Sciences, School of Pharmacy and Health Profession, Creighton University, Omaha, Nebraska, United States of America
| | - Alekha K. Dash
- Department of Pharmacy Sciences, School of Pharmacy and Health Profession, Creighton University, Omaha, Nebraska, United States of America
| |
Collapse
|
2
|
Deodhar S, Sillman B, Bade AN, Avedissian SN, Podany AT, McMillan JM, Gautam N, Hanson B, Dyavar Shetty BL, Szlachetka A, Johnston M, Thurman M, Munt DJ, Dash AK, Markovic M, Dahan A, Alnouti Y, Yazdi A, Kevadiya BD, Byrareddy SN, Cohen SM, Edagwa B, Gendelman HE. Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation. Nat Commun 2022; 13:3226. [PMID: 35680875 PMCID: PMC9184486 DOI: 10.1038/s41467-022-30902-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Accepted: 05/20/2022] [Indexed: 11/09/2022] Open
Abstract
Ultra-long-acting integrase strand transfer inhibitors were created by screening a library of monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led to an 18-carbon chain modified ester prodrug nanocrystal (coined NM2DTG) with the potential to sustain yearly dosing. Here, we show that the physiochemical and pharmacokinetic (PK) formulation properties facilitate slow drug release from tissue macrophage depot stores at the muscle injection site and adjacent lymphoid tissues following single parenteral injection. Significant plasma drug levels are recorded up to a year following injection. Tissue sites for prodrug hydrolysis are dependent on nanocrystal dissolution and prodrug release, drug-depot volume, perfusion, and cell-tissue pH. Each affect an extended NM2DTG apparent half-life recorded by PK parameters. The NM2DTG product can impact therapeutic adherence, tolerability, and access of a widely used integrase inhibitor in both resource limited and rich settings to reduce HIV-1 transmission and achieve optimal treatment outcomes.
Collapse
Affiliation(s)
- Suyash Deodhar
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Brady Sillman
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA.,Nebraska Nanomedicine Production Plant, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Aditya N Bade
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Sean N Avedissian
- Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Anthony T Podany
- Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - JoEllyn M McMillan
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Nagsen Gautam
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Brandon Hanson
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Bhagya L Dyavar Shetty
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Adam Szlachetka
- Nebraska Nanomedicine Production Plant, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Morgan Johnston
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Michellie Thurman
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Daniel J Munt
- Department of Pharmacy Sciences, Creighton University, Omaha, NE, 68178, USA
| | - Alekha K Dash
- Department of Pharmacy Sciences, Creighton University, Omaha, NE, 68178, USA
| | - Milica Markovic
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Arik Dahan
- Department of Clinical Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel
| | - Yazen Alnouti
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Alborz Yazdi
- Exavir Therapeutics, Inc., New York, NY, 10012, USA
| | - Bhavesh D Kevadiya
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Siddappa N Byrareddy
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Samuel M Cohen
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Benson Edagwa
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA. .,Nebraska Nanomedicine Production Plant, University of Nebraska Medical Center, Omaha, NE, 68198, USA. .,Exavir Therapeutics, Inc., New York, NY, 10012, USA.
| | - Howard E Gendelman
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA. .,Nebraska Nanomedicine Production Plant, University of Nebraska Medical Center, Omaha, NE, 68198, USA. .,Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA. .,Exavir Therapeutics, Inc., New York, NY, 10012, USA.
| |
Collapse
|
3
|
Munt DJ, Qi Y, Dash AK. Comparative evaluation of the Munt-Dash air-interface diffusion chamber and Franz chamber for the in vitro examination of topical spray formulations. Int J Pharm 2021; 608:121127. [PMID: 34560210 DOI: 10.1016/j.ijpharm.2021.121127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 09/05/2021] [Accepted: 09/19/2021] [Indexed: 11/16/2022]
Abstract
In vitro diffusion testing of topical formulations has long been examined using Franz diffusion chambers, however, Franz chambers are typically used with relatively large volumes, lack the air/membrane interface present in vivo, and do not account for changes in formula characteristics as solvent evaporates. Here we present our patented Munt-Dash diffusion chamber designed for direct spray application onto a model membrane. Diffusion characteristics from topical spray formulations utilizing both the Munt-Dash chamber and Franz diffusion chambers were evaluated and compared. Using diclofenac sodium and lidocaine hydrochloride as model drugs and shed snakeskin as a model for stratum corneum, test solutions were applied to Franz diffusion chambers using a pipette and to the Munt-Dash chamber using a high-speed syringe pump and sprayer. Both chambers presented permeability data consistent with previously reported in vitro and in vivo studies. Significant differences were observed in permeability by formulation and temperature. This suggests that although Franz chambers produce relevant data, the failure to account for small volumes and drying during application may produce misleading results. The Munt-Dash chamber may improve in vitro testing by providing these factors. This data suggests the Munt-Dash chamber is a suitable alternative to the Franz chamber for topical spray formulations.
Collapse
Affiliation(s)
- Daniel J Munt
- Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University, Omaha, NE, United States
| | - Yongyue Qi
- Department of Occupational Therapy, School of Pharmacy and Health Professions, Creighton University, Omaha, NE, United States
| | - Alekha K Dash
- Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University, Omaha, NE, United States.
| |
Collapse
|
4
|
Anders JPV, Neltner TJ, Smith RW, Keller JL, Housh TJ, Daugherty FJ, Tempesta MS, Dash AK, Munt DJ, Schmidt RJ, Johnson GO. The effects of phosphocreatine disodium salts plus blueberry extract supplementation on muscular strength, power, and endurance. J Int Soc Sports Nutr 2021; 18:60. [PMID: 34503541 PMCID: PMC8427883 DOI: 10.1186/s12970-021-00456-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Accepted: 07/01/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Numerous studies have demonstrated the efficacy of creatine supplementation for improvements in exercise performance. Few studies, however, have examined the effects of phosphocreatine supplementation on exercise performance. Furthermore, while polyphenols have antioxidant and anti-inflammatory properties, little is known regarding the influence of polyphenol supplementation on muscular strength, power, and endurance. Thus, the purpose of the present study was to compare the effects of 28 days of supplementation with phosphocreatine disodium salts plus blueberry extract (PCDSB), creatine monohydrate (CM), and placebo on measures of muscular strength, power, and endurance. METHODS Thirty-three men were randomly assigned to consume either PCDSB, CM, or placebo for 28 days. Peak torque (PT), average power (AP), and percent decline for peak torque (PT%) and average power (AP%) were assessed from a fatigue test consisting of 50 maximal, unilateral, isokinetic leg extensions at 180°·s- 1 before and after the 28 days of supplementation. Individual responses were assessed to examine the proportion of subjects that exceeded a minimal important difference (MID). RESULTS The results demonstrated significant (p < 0.05) improvements in PT for the PCDSB and CM groups from pre- (99.90 ± 22.47 N·m and 99.95 ± 22.50 N·m, respectively) to post-supplementation (119.22 ± 29.87 N·m and 111.97 ± 24.50 N·m, respectively), but no significant (p = 0.112) change for the placebo group. The PCDSB and CM groups also exhibited significant improvements in AP from pre- (140.18 ± 32.08 W and 143.42 ± 33.84 W, respectively) to post-supplementation (170.12 ± 42.68 W and 159.78 ± 31.20 W, respectively), but no significant (p = 0.279) change for the placebo group. A significantly (p < 0.05) greater proportion of subjects in the PCDSB group exceeded the MID for PT compared to the placebo group, but there were no significant (p > 0.05) differences in the proportion of subjects exceeding the MID between the CM and placebo groups or between the CM and PCDSB groups. CONCLUSIONS These findings indicated that for the group mean responses, 28 days of supplementation with both PCDSB and CM resulted in increases in PT and AP. The PCDSB, however, may have an advantage over CM when compared to the placebo group for the proportion of individuals that respond favorably to supplementation with meaningful increases in muscular strength.
Collapse
Affiliation(s)
- John Paul V Anders
- Department of Nutrition and Human Sciences, University of Nebraska-Lincoln, Lincoln, NE, 68510, USA.
| | - Tyler J Neltner
- Department of Nutrition and Human Sciences, University of Nebraska-Lincoln, Lincoln, NE, 68510, USA
| | - Robert W Smith
- Department of Nutrition and Human Sciences, University of Nebraska-Lincoln, Lincoln, NE, 68510, USA
| | - Joshua L Keller
- Department of Health, Kinesiology and Sport, University of South Alabama, Mobile, AL, 36688, USA
| | - Terry J Housh
- Department of Nutrition and Human Sciences, University of Nebraska-Lincoln, Lincoln, NE, 68510, USA
| | | | | | - Alekha K Dash
- Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Omaha, NE, 68178, USA
| | - Daniel J Munt
- Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Omaha, NE, 68178, USA
| | - Richard J Schmidt
- Department of Nutrition and Human Sciences, University of Nebraska-Lincoln, Lincoln, NE, 68510, USA
| | - Glen O Johnson
- Department of Nutrition and Human Sciences, University of Nebraska-Lincoln, Lincoln, NE, 68510, USA
| |
Collapse
|